{"Clinical Trial ID": "NCT00191451", "Intervention": ["INTERVENTION 1:", "- HER2+", "Human epidermal growth factor Receptor 2 positive: Gemcitabine + Carboplatin + Herceptine.", "Gemcitabine: 1st day of the 14-day cycle (Cycles 1 to 9): 1500 milligrams per square metre (mg/m2) by the intravenous route (IV) (30 minutes of infusion); Carboplatin: 1st day of the 14-day cycle (Cycles 1 to 9): Carboplatin region under the curve (AUC) = 2.5 by the intravenous route (IV) (30 to 60 minutes of infusion); Herceptin: 1st day of the 14-day cycle (Cycle 1: 8 milligrams per kilogram (mg/kg) by the intravenous route (IV) (90 minutes of infusion); 1st day of the 14-day cycle (Cycles 2 to 9: 4 mg/kg IV (30 minutes of infusion); 1st day of the 21-day cycle (Cycles 10 to +): 6 mg/kg IV (30 minutes of infusion).", "INTERVENTION 2:", "- HER2- (Taxe-)", "Human epidermal growth factor Receptor 2 negative: Gemcitabine + Carboplatin. (taxane na\u00efve patients).", "Gemcitabine: Day 1 of the 14-day cycle (Cycles 1-9):1500 milligram per square metre (mg/m2) intravenously (IV) (30 minutes of infusion); Carboplatin: Day 1 of the 14-day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenously (IV) (30-60 minutes of infusion)."], "Eligibility": ["Incorporation criteria:", "Diagnosis of metastatic breast cancer", "\u2022 Capable of visiting the doctor's office at least every 14 days during treatment", "You can take care of yourself, even if you can't work or take part in other normal activities.", "Your blood results should be adequate for treatment.", "If you are a woman of childbearing potential and the test is negative for pregnancy, use a reliable birth control method during and for three months following the last dose of the drug under study.", "- Exclusion criteria:", "Have received gemcitabine, paraplatin or trastuzumab for your cancer.", "Be pregnant or breast-feeding", "Have cancer in the brain and has not been treated", "Have another active cancer in addition to breast cancer", "Have received a stem cell or bone marrow transplant for haematological cancer (blood type)"], "Results": ["Performance measures:", "Overall response of tumours", "Complete response=disappearance of all target lesions; Partial response=30% decrease in the sum of the longest diameter of target lesions; Progressive illness=20% increase in the sum of the longest diameter of target lesions; Stable illness=small changes that do not meet the above criteria.", "Time limit: start of progression/recurrence of disease (up to 3.5 years)", "Results 1:", "Title of the arm/group: HER2+", "Description of the arm/group: Human epidermal growth factor Receptor 2 positive: Gemcitabine + Carboplatin + Herceptine.", "Gemcitabine: 1st day of the 14-day cycle (Cycles 1 to 9): 1500 milligrams per square metre (mg/m2) by the intravenous route (IV) (30 minutes of infusion); Carboplatin: 1st day of the 14-day cycle (Cycles 1 to 9): Carboplatin region under the curve (AUC) = 2.5 by the intravenous route (IV) (30 to 60 minutes of infusion); Herceptin: 1st day of the 14-day cycle (Cycle 1: 8 milligrams per kilogram (mg/kg) by the intravenous route (IV) (90 minutes of infusion); 1st day of the 14-day cycle (Cycles 2 to 9: 4 mg/kg IV (30 minutes of infusion); 1st day of the 21-day cycle (Cycles 10 to +): 6 mg/kg IV (30 minutes of infusion).", "Total number of participants analysed: 50", "Type of measurement: Number", "Unit of Measure: Participants Complete Response (CR): 6", "Partial response (PR): 26", "Stable disease (SD): 12", "Progressive diseases (PD): 4", "Non-electable (NE): 2", "Results 2:", "Title of arm/group: HER2- (Taxane-)", "Description arm/group: Human epidermal growth factor Receptor 2 negative: Gemcitabine + Carboplatin. (taxane na\u00efve patients).", "Gemcitabine: Day 1 of the 14-day cycle (Cycles 1-9):1500 milligram per square metre (mg/m2) intravenously (IV) (30 minutes of infusion); Carboplatin: Day 1 of the 14-day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenously (IV) (30-60 minutes of infusion).", "Total number of participants analysed: 47", "Type of measurement: Number", "Unit of Measure: Participants Complete Response (CR): 0", "- Partial response (PR): 13", "Stable disease (SD): 20", "Progressive diseases (PD): 12", "Non-electable (NE): 2"], "Adverse Events": ["Undesirable Events 1:", "Total: 10/50 (20.00 per cent)", "Anemia 0/50 (0.00 %)", "Febrile neutropenia 0/50 (0.00 %)", "Neutropenia 0/50 (0.00 %)", "Thrombocytopenia 0/50 (0.00 %)", "Diastolic dysfunction 0/50 (0.00 %)", "Tachycardia 0/50 (0.00 %)", "Intestinal occlusion 0/50 (0.00 %)", "Nausea 1/50 (2.0%)", "- esophageal spasm 0/50 (0.00 %)", "Oesophagitis 0/50 (0.00 %)", "0/50 (0.00 per cent)", "Adverse Events 2:", "Total: 11/48 (22.92 per cent)", "Anemia 4/48 (8.33%)", "- Febrile neutropenia 0/48 (0.00 %)", "Neutropenia 2/48 (4.17 per cent)", "Thrombocytopenia 2/48 (4.17 per cent)", "Diastolic dysfunction 1/48 (2.08%)", "Tachycardia 1/48 (2.08%)", "Intestinal occlusion 0/48 (0.00 %)", "Nausea 0/48 (0.00 %)", "Esophagian spasm 1/48 (2.08%)", "Oesophagitis 0/48 (0.00 %)", "Withdrawal 1/48 (2.08 per cent)"]}